Off-label treatment with Mirum Pharmaceuticals’ maralixibat led to clinically meaningful reductions in severe itching, or pruritus, in five children…
Articles by Steve Bryson, PhD
The U.S. Food and Drug Administration (FDA) has turned down a request by Intercept Pharmaceuticals for the full approval of…
Women who conceive with the help of in vitro fertilization (IVF) — a commonly used assisted reproductive technology — are…
Signs of improved liver health are evident in biomarker and liver scarring assessments of people with metabolic-associated steatohepatitis or MASH…
A study showed that a genetic mutation associated with metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty…
Two weeks of oral methylprednisolone twice a day as an add-therapy significantly lowered signs of liver damage and inflammation among…
A blood-based biomarker of body-wide inflammation called a low systemic immune-inflammation index (SII) before a standard Kasai surgical procedure…
Six months of Calliditas Therapeutics‘ investigational therapy setanaxib safely and significantly reduced signs of liver damage in people with…
Dosing has begun in a Phase 2 clinical trial evaluating the safety and efficacy of DD01 in people with one of…
In its efforts to connect diagnosed but untreated hepatitis B or C patients with physicians, the Center for…